News

Strengthening our resolve for research and advocacy: A letter from our President

By Associate Professor Des Graham

On behalf of the MS Australia Board, I am delighted to present the MS Australia ‘A world without MS: Strategic Plan 2022–2026’.

A single national body now represents Australians living with MS after an extensive review of our governance and operations in 2019 and 2020. The MS Australia Board endorsed an independent expert’s recommendation to bring MS Australia and its research subsidiary MS Research Australia together, which heralds a new era for people living with MS. In the shadow of a tough operating market for not-for-profits following a series of major national structural and regulatory reforms, the review identified ways to better meet the current and future needs of people living with MS and the ongoing pursuit for a cure.

The resultant changes mean MS Australia is becoming a more robust and efficient organisation. This has also strengthened our resolve and capacity to advance our research agenda alongside our tireless advocacy for people living with MS. The governance realignment is nearly complete, and with the appointment of Rohan Greenland, MS Australia’s new CEO, we are excited about the future. In particular, the implementation of our inaugural Strategic Plan and greater sustainable partnerships with our state and territory Member Organisations, consumers, carers, researchers, institutions, and other stakeholders.

This Strategic Plan has drawn on extensive feedback from people living with MS, their family members, friends and others affected by MS. I am delighted that so many stakeholders trusted us and shared their views. Some 3,000 people responded to our 2021 Research and Advocacy Priorities Survey – an incredible result and quite possibly the largest point in time feedback from the Australian MS community! Many others participated in dynamic focus groups and feedback sessions. We also heard from health professionals, our member organisations, staff and key stakeholders in our networks in Australia and overseas. I am confident that our process has been robust, inclusive and well informed. I want to thank everyone who participated in our strategic planning process.

Significantly, the most important priority identified during the feedback process is for us to supercharge funding for research. It is the pinnacle and aligns with our mission to accelerate research toward the prevention, better treatments and a cure for MS. You will see this priority permeates a large part of our strategic intent.

In closing, I would like to thank all Australians who have directly and indirectly contributed to MS Australia’s agenda to advocate for all people living with MS and carers and supercharge our research agenda to find the cure. I look forward to working with each and every one of you, keen to help ensure MS Australia’s future success.

To view our ‘A world without MS: Strategic Plan 2022–2026’, please click here.

Associate Professor Des Graham

Associate Professor Des Graham

With over thirty-five years’ experience in health and human services, Des has held senior executive public sector positions across a broad range of portfolios responsible for clinical, service delivery and policy and planning portfolios. He was also the inaugural CEO for the Mental Health Council of Australia and continues to have engagements with a broad range of non-government organisations. Des has represented jurisdictions on a broad range of national forums including the Council of Australian Government committees. Of note was Des’s role in national committees responsible for the moulding and implementation of the Rudd Health Reforms and the NDIS. Des has held an adjunct Associate Professor position with the University of Tasmania, College of Health and Medicine and is active in the Menzies Institute for Medical Research MS Flagship. Professionally, one of Des’ most prized achievements was the dedication of a Human Rights and Equal Opportunity Award to the Mental Health Council of Australia for his services to consumer and carer participation in health service planning and individual care, a principle he continues to advocate strongly for today.
paediatricms

Early High-Efficacy Therapy in Paediatric MS Reduces Risk of Reaching Key Disability Milestones

New study reveals early highly effective therapy significantly reduces disability...
network-web

How the Big MS Data network is advancing MS research

The Big MS Data network consists of multiple national and...

Want us to keep you in the loop? Subscribe today!

  • Enter your details

Read More
rohan greenland2021 Priorities Survey

Newsletter subscription

  • Enter your details

Strengthening our resolve for research and advocacy: A letter from our President